Apnimed, Inc. (APMD) Stock Forecast
APMD analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $50.33 average of analyst targets
- Upside to target
- +183.4% from the latest close
- Next earnings
- December 8, 2026
- 52-week range
- $16.00 – $32.55
APMD analyst ratings
4 analystsNumber of analysts at each rating.
APMD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
APMD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.60 | −$0.61 | −$0.59 | — | — | 2 |
| Current fiscal year (2026) | −$0.06 | −$0.06 | −$0.06 | — | — | 1 |
| Next fiscal year (2027) | −$3.98 | −$5.55 | −$1.39 | −$0.06 | −6,525.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
APMD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 3 |
| Current fiscal year (2026) | $90.8M | $84.8M | $96.9M | — | 2 |
| Next fiscal year (2027) | $22.4M | $13.8M | $32.2M | −75.3% | 4 |
APMD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
APMD revenue: reported and forecast
APMD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | −$0.40 | −$0.60 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | −$0.21 | −$0.06 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | −$4.02 | −$3.98 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
APMD earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; APMD beat in 1 of 1.
What analysts expect from APMD
4 analysts cover Apnimed; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $50.33, 183.4% above the latest close of $17.76. Analysts expect earnings of −$0.06 per share for 2026. For 2027 the average estimate is −$3.98 per share on revenue of $22.4 million. Apnimed beat the EPS estimate in 1 of the last 1 quarters.
Related: APMD income statement, APMD key metrics, APMD chart. See the APMD stock overview for the latest quote and news.
APMD forecast FAQ
What is Apnimed's price target?
The average analyst price target for Apnimed is $50.33, 183.4% above the latest close of $17.76.
Is Apnimed a buy, hold or sell?
Of 4 analysts covering Apnimed, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Apnimed's EPS forecast?
Analysts forecast −$0.06 per share for 2026 (range −$0.06 to −$0.06); for 2027 the estimate is −$3.98.
What is Apnimed's revenue forecast?
The average revenue estimate for 2026 is $90.8 million; for 2027 it is $22.4 million.
When does Apnimed report earnings?
Apnimed is expected to report results for the quarter ending September 30, 2026 on December 8, 2026.
Does Apnimed usually beat earnings estimates?
Apnimed reported EPS at or above the analyst estimate in 1 of the last 1 quarters.